AUA 2024 Prostate Cancer

Viewing 1-20 of 65 articles

AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC +/- HRR Mutations

AUA 2024: Evaluating AI Assistance in Prostate bpMRI Interpretation: A Multi-Reader Study

AUA 2024: Panel Discussion: Tricks and Tips of Penile Prosthesis Surgery

AUA 2024: Crossfire: Controversies in Urology: Detrusor Underactivity in Men in Retention: To TURP or Not to TURP?

AUA 2024: Crossfire: Controversies in Urology: Testosterone Therapy May Be Reasonably Offered to Men on Active Surveillance – Pro/Con

AUA 2024: Can Genitourinary Cancer Survivors Understand Quality of Life (QoL) Questionnaires? Assessing the Readability of Commonly Used Urologic Oncology QoL Instruments

AUA 2024: Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand?

AUA 2024: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

AUA 2024: Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients with High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy (PRELUDE Trial)

AUA 2024: Updates on Metastasis Directed Therapy

AUA 2024: Darolutamide Real-World Doublet and Triplet Utilization in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): US Community Urology Setting

AUA 2024: Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence

AUA 2024: Evaluation of Response to 177Lu-PSMA-617 by Site Specific Disease in Metastatic Castrate-Resistant Prostate Cancer

AUA 2024: Major Complications and Adverse Events of SpaceOAR Hydrogel: An Analysis of the Manufacturer and User Facility Device Experience Database

AUA 2024: Review of SpaceOAR Complications in The MAUDE Database with Focus on Rectal Wall Infiltration

AUA 2024: Temporal and Regional Patterns of Prostate Cancer Positron Emission Tomography Imaging Among Commercial Insurance Beneficiaries in the United States

AUA 2024: PSMA-PET Guided Metastasis Directed Therapy for Oligometastatic Prostate Cancer

AUA 2024: Genetic Testing in Prostate Cancer: The Role of the Urologists

AUA 2024: Prostate Cancer: Dissemination and Availability of Minimally Invasive Treatments to Underserved Populations

AUA 2024: Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients with Biochemical Recurrent Prostate Cancer: A Retrospective Cohort Study

1
2
3
4